Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 14
Private Equity 15
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 15
Partnerships 16
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 16
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 17
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 18
Inovio Pharma and Regeneron Pharma Enter into Agreement 19
Indivumed Enters into Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 21
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 23
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 24
Bayer Enters into Co-Development Agreement with Regeneron Pharma 25
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 26
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 27
Regeneron Pharma Enters into Development Agreement with BARDA 28
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 29
Regeneron Pharma Amends Co-Development Agreement with Sanofi 31
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 32
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 33
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 34
Licensing Agreements 36
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 36
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 37
Regeneron Pharma Enters into Licensing Agreement with MedImmune 39
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 40
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 41
Debt Offering 42
Regeneron Pharma Completes Private Placement Of 1.875% Convertible Senior Notes Due 2016 For US$400 Million 42
Regeneron Pharmaceuticals Inc – Key Competitors 43
Regeneron Pharmaceuticals Inc – Key Employees 44
Regeneron Pharmaceuticals Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Financial Announcements 48
Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 48
Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 51
May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 54
Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 57
Nov 04, 2016: Regeneron Reports Third Quarter 2016 Financial and Operating Results 61
Aug 04, 2016: Regeneron Reports Second Quarter 2016 Financial and Operating Results 64
May 05, 2016: Regeneron Reports First Quarter 2016 Financial and Operating Results 67
Feb 09, 2016: Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results 70
Corporate Communications 73
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 73
Sep 12, 2016: Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors 74
Legal and Regulatory 75
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 75
Feb 02, 2016: Kymab Succeeds in Revoking Regeneron’s UK VelocImmune Patents 76
Government and Public Interest 77
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World’s Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 77
May 26, 2016: Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search 79
Product News 81
05/24/2016: New Cholesterol Treatment Now Available for Canadians 81
05/06/2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke 82
04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 84
02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 85
Product Approvals 86
Jul 05, 2016: Regeneron and Sanofi Announce Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia in Japan 86
Jun 22, 2016: NICE Green Lights Cholesterol-Lowering Treatment Praluent (alirocumab) For NHS Funding 88
Feb 08, 2016: NICE issues draft guidance on alirocumab for lipid disorder 90
Clinical Trials 91
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 91
Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 93
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 94
Nov 17, 2016: Regeneron and Sanofi Announce Praluent (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis 96
Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016 97
Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 99
Mar 30, 2016: Regeneron and Sanofi to Present Phase 3 Praluent (alirocumab) Injection Clinical Trial Data at ACC.16 101
Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 103
Appendix 105
Methodology 105
About GlobalData 105
Contact Us 105
Disclaimer 105
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 14
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 15
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 16
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 17
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 18
Inovio Pharma and Regeneron Pharma Enter into Agreement 19
Indivumed Enters into Agreement with Regeneron Pharma 20
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 21
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 23
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 24
Bayer Enters into Co-Development Agreement with Regeneron Pharma 25
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 26
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 27
Regeneron Pharma Enters into Development Agreement with BARDA 28
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 29
Regeneron Pharma Amends Co-Development Agreement with Sanofi 31
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 32
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 33
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 34
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 36
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 37
Regeneron Pharma Enters into Licensing Agreement with MedImmune 39
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 40
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 41
Regeneron Pharma Completes Private Placement Of 1.875% Convertible Senior Notes Due 2016 For US$400 Million 42
Regeneron Pharmaceuticals Inc, Key Competitors 43
Regeneron Pharmaceuticals Inc, Key Employees 44
Regeneron Pharmaceuticals Inc, Other Locations 46
Regeneron Pharmaceuticals Inc, Subsidiaries 46